title: The pharmacological management of osteoporosis.
abstract: Pharmacotherapy is effective in decreasing the incidence of osteoporotic fracture, morbidity, and mortality. This benefit is pronounced in patients at highest risk for fracture: those with prior osteoporotic fracture, very low bone mineral density, or receiving chronic corticosteroid treatment. We review the best pharmacotherapeutic options currently available for treating osteoporosis.
authors.affiliation: Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St. Louis, USA. ariek@dom.wustl.edu
authors.forename: Amy E
authors.initials: AE
authors.lastname: Riek
authors.forename: Dwight A
authors.initials: DA
authors.lastname: Towler
mesh_terms: D015502:Absorptiometry, Photon; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D000069448:Denosumab; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000453:epidemiology; D053245:RANK Ligand / Q000627:therapeutic use; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D020845:Selective Estrogen Receptor Modulators; D019379:Teriparatide; D000069448:Denosumab